1. Caplan ES. Role of immunomodulator therapy in sepsis. Am J Surg 1993 Feb; 165 Suppl.: 20S–5S
2. Lynn WA. Prospects for the immunotherapy of septic shock. Curr Opin Invest Drugs 1993 Sep; 2: 973–81
3. Quintiliani R, Cooper B, Maderazo E, et al. Gram-negative sepsis: pathophysiology of infection, development of polyclonal, monoclonal human hybrid and murine anti-endotoxin antibodies. Hosp Formul 1991; 26(12): 960–8
4. Seelen MA, Athanassiou P, Lynn WA, et al. The anti-lipid A monoclonal antibody E5 binds to rough Gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes. Immunology 1995 Apr; 84: 653–61
5. Parent JB, Gazzano-Santoro H, Wood DM, et al. Reactivity of monoclonal antibody E5® with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides. Circ Shock 1992 Sep; 38: 63–73